Viewing Study NCT06768658


Ignite Creation Date: 2025-12-25 @ 12:09 AM
Ignite Modification Date: 2025-12-30 @ 3:38 PM
Study NCT ID: NCT06768658
Status: TERMINATED
Last Update Posted: 2025-07-02
First Post: 2025-01-06
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS)
Sponsor: Takeda
Organization:

Study Overview

Official Title: A Randomized, Double-Blind, Placebo-Controlled Repeated Crossover Study to Evaluate the Safety and Tolerability of Intermittent Single Doses of TAK-951 in the Abortive Treatment of Subjects With Cyclic Vomiting Syndrome
Status: TERMINATED
Status Verified Date: 2025-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Due to business reasons prior to first subject dosed.
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a study of TAK-951 in participants with cyclic vomiting syndrome (CVS).

The main aims of this study are as follows:

* To check for side effects from treatment with TAK-951.
* To learn how much TAK-951 participants can receive without getting side effects from it.
* To check how much TAK-951 stays in the blood over time to work out the best dose.
* The dose of TAK-951 will be checked to see how much stays in their blood over time.
* To see if it is possible to give treatment at home. Participants will be given TAK-951 injected just under the skin (subcutaneous or SC).
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: